These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 2692428

  • 1. The development of molecular vaccines against malaria sporozoites.
    Ballou WR, Young JF, Cryz SJ, Sadoff JC.
    Adv Exp Med Biol; 1989; 251():295-313. PubMed ID: 2692428
    [No Abstract] [Full Text] [Related]

  • 2. Proteosome-hydrophobic 'foot' malaria peptide vaccines for Plasmodium falciparum and P. vivax.
    Lowell GH, Ballou WR, Smith LF, Zollinger WD, Hockmeyer WT.
    Trans R Soc Trop Med Hyg; 1989; 83 Suppl():101-2. PubMed ID: 2696152
    [Abstract] [Full Text] [Related]

  • 3. Plasmodium berghei subunit vaccine: repeat synthetic peptide of circumsporozoite protein comprising T- and B-cell epitopes fails to confer immunity.
    Migliorini P, Boulanger N, Betschart B, Corradin G.
    Scand J Immunol; 1990 Feb; 31(2):237-42. PubMed ID: 1689867
    [Abstract] [Full Text] [Related]

  • 4. Sporozoite immunity and vaccine development.
    Hockmeyer WT, Ballou WR.
    Prog Allergy; 1988 Feb; 41():1-14. PubMed ID: 3043419
    [No Abstract] [Full Text] [Related]

  • 5. Identification of a peptide sequence of the 25 kD surface protein of Plasmodium falciparum recognized by transmission-blocking monoclonal antibodies: implications for synthetic vaccine development.
    van Amerongen A, Sauerwein RW, Beckers PJ, Meloen RH, Meuwissen JH.
    Parasite Immunol; 1989 Jul; 11(4):425-8. PubMed ID: 2674864
    [No Abstract] [Full Text] [Related]

  • 6. The real difficulties for malaria sporozoite vaccine development: nonresponsiveness and antigenic variation.
    Good MF, Kumar S, Miller LH.
    Immunol Today; 1988 Nov; 9(11):351-5. PubMed ID: 3076406
    [No Abstract] [Full Text] [Related]

  • 7. [Immunologic prevention of malaria].
    Wagner WH.
    Med Monatsschr Pharm; 1990 Jul; 13(7):209-15. PubMed ID: 1695990
    [No Abstract] [Full Text] [Related]

  • 8. Immunization trials with the ring-infected erythrocyte surface antigen of Plasmodium falciparum in owl monkeys (Aotus vociferans).
    Collins WE, Pappaioanou M, Anders RF, Campbell GH, Brown GV, Kemp DJ, Broderson JR, Coppel RL, Skinner JC, Procell PM.
    Am J Trop Med Hyg; 1988 Mar; 38(2):268-82. PubMed ID: 3281493
    [Abstract] [Full Text] [Related]

  • 9. Vaccines for human malaria: epidemiological and immunological perspectives.
    Webster HK, Diggs CL, Ballou WR, Chulay JD.
    Southeast Asian J Trop Med Public Health; 1988 Sep; 19(3):375-89. PubMed ID: 3064321
    [No Abstract] [Full Text] [Related]

  • 10. Evidence for a 6.5-day minimum exoerythrocytic cycle for Plasmodium falciparum in humans and confirmation that immunization with a synthetic peptide representative of a region of the circumsporozoite protein retards infection.
    Murphy JR, Baqar S, Davis JR, Herrington DA, Clyde DF.
    J Clin Microbiol; 1989 Jul; 27(7):1434-7. PubMed ID: 2671011
    [Abstract] [Full Text] [Related]

  • 11. Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens.
    Quakyi IA, Otoo LN, Pombo D, Sugars LY, Menon A, De Groot AS, Johnson A, Alling D, Miller LH, Good MF.
    Am J Trop Med Hyg; 1989 Aug; 41(2):125-34. PubMed ID: 2672834
    [Abstract] [Full Text] [Related]

  • 12. Synthetic peptide vaccine confers protection against murine malaria.
    Zavala F, Tam JP, Barr PJ, Romero PJ, Ley V, Nussenzweig RS, Nussenzweig V.
    J Exp Med; 1987 Nov 01; 166(5):1591-6. PubMed ID: 3316473
    [Abstract] [Full Text] [Related]

  • 13. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA, Zakeri S, Rafati S, Salmanian AH, Djadid ND.
    Parasite Immunol; 2011 Nov 01; 33(11):594-608. PubMed ID: 21883290
    [Abstract] [Full Text] [Related]

  • 14. T cell functions in Plasmodium falciparum and other malarias.
    Troye-Blomberg M, Perlmann P.
    Prog Allergy; 1988 Nov 01; 41():253-87. PubMed ID: 3043421
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of antibodies to sporozoites in Plasmodium falciparum malaria and correlation with protection.
    Webster HK, Brown AE, Chuenchitra C, Permpanich B, Pipithkul J.
    J Clin Microbiol; 1988 May 01; 26(5):923-7. PubMed ID: 2454941
    [Abstract] [Full Text] [Related]

  • 16. An update on candidate malaria vaccines.
    Mitchell GH.
    Parasitology; 1989 May 01; 98 Suppl():S29-47. PubMed ID: 2657600
    [No Abstract] [Full Text] [Related]

  • 17. Parasitology. Malaria--from infants to genomics to vaccines.
    Long CA, Hoffman SL.
    Science; 2002 Jul 19; 297(5580):345-7. PubMed ID: 12130768
    [No Abstract] [Full Text] [Related]

  • 18. Malaria vaccines: results of human trials and directions of current research.
    Cattani JA.
    Exp Parasitol; 1989 Feb 19; 68(2):242-7. PubMed ID: 2647511
    [Abstract] [Full Text] [Related]

  • 19. Immunization of owl monkeys with a combination of Plasmodium falciparum asexual blood-stage synthetic peptide antigens.
    Ruebush TK2nd, Campbell GH, Moreno A, Patarroyo ME, Collins WE.
    Am J Trop Med Hyg; 1990 Oct 19; 43(4):355-66. PubMed ID: 2240363
    [Abstract] [Full Text] [Related]

  • 20. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus.
    Etlinger HM, Altenburger W.
    Vaccine; 1991 Jul 19; 9(7):470-2. PubMed ID: 1716807
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.